Artelo Biosciences, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Amounts are in U.S. dollars; financial statement amounts are in thousands unless noted. Artelo is a clinical-stage biopharmaceutical company developing therapies targeting lipid-signaling pathways. It has no approved products and has not generated revenue.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1,507 | $1,235 |
| General and administrative expense | $1,082 | $1,057 |
| Total operating expenses / operating loss | $2,589 / $(2,589) | $2,292 / $(2,292) |
| Other income | $106 | $124 |
| Net loss | $(2,483) | $(2,168) |
| Basic and diluted loss per share | $(0.78) | $(0.76) |
| Operating cash flow | $(2,942) | $(2,186) |
| Cash and cash equivalents | $1,195 | $2,815 at Dec. 31, 2023 |
| Trading marketable securities | $6,414 | $7,611 at Dec. 31, 2023 |
| Working capital | $7,467 | $9,689 at Dec. 31, 2023 |
| Total liabilities | $817 | $1,291 at Dec. 31, 2023 |
Cash, cash equivalents and investments totaled $7.6 million at quarter-end. The filing reports no borrowings; operating lease liabilities were $127,000, including $31,000 current. Gross margin is not meaningful because the company had no revenue. Cash used in investing activities was $1.269 million, primarily reflecting net purchases and dispositions of marketable securities; financing provided $55,000 from common-share issuance.
Changes versus the comparable period
- Operating expenses increased $297,000, or about 13%, chiefly from a $272,000 increase in R&D expense associated with third-party subcontractor work.
- Net loss increased $315,000, from $2.168 million to $2.483 million. Loss per share rose from $0.76 to $0.78; weighted-average shares increased to 3.197 million from 2.856 million.
- Operating cash use increased $756,000. Cash and investments declined from $10.426 million at year-end to $7.609 million at March 31, 2024; cash alone fell $1.620 million during the quarter.
Outlook, programs and risks
- Management expects existing cash resources to fund planned operations into the second half of 2025, but says further funding will be needed to continue beyond that period. The filing also warns that additional financing may be needed in the near future and that funding may not be available on acceptable terms.
- The company may seek capital through equity or debt offerings, licensing, or other arrangements. Its May 2022 equity line allows up to $20 million in stock purchases over 36 months, subject to conditions; $622,000 had been raised through March 31, including $55,000 in Q1. A $75 million shelf registration is effective, subject to a limit tied to one-third of public float in any 12-month period. Further equity issuance could dilute shareholders.
- ART27.13 is in the Phase 2a portion of the CAReS study for cancer-related anorexia. Nine sites were open as of March 2024; full enrollment of up to 40 patients was projected by year-end 2024. ART26.12 remains preclinical, with first-in-human studies anticipated in the second half of 2024, dependent on study resources and regulatory review. ART12.11 is also preclinical.
- Key risks include clinical, regulatory, manufacturing and enrollment uncertainty; reliance on third-party providers; financing needs; intellectual-property and licensing obligations; and risks associated with cannabinoid regulation and controlled-substance requirements. UK R&D tax-credit eligibility may be reduced for certain costs outside the UK for accounting periods beginning on or after April 1, 2024.
- The company reported no material legal proceedings and no material off-balance-sheet arrangements. Management concluded disclosure controls were effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether CAReS enrollment and the projected year-end 2024 timeline were achieved, and what subsequent trial updates show.
- Whether ART26.12 regulatory-enabling work supports the anticipated second-half 2024 first-in-human start.
- The pace of cash burn and whether the stated runway into the second half of 2025 remains supportable as development costs change.
- Available capacity, conditions and actual proceeds under the equity line and shelf registration, including potential dilution.
- The financial effect of UK R&D tax-credit changes and any resulting change to operating plans or financing needs.